ImmuCell Corp. (ICCC)
9.84
-0.06
(-0.61%)
USD |
NASDAQ |
Sep 08, 16:00
9.97
+0.13
(+1.32%)
After-Hours: 20:00
ImmuCell PE Ratio : 117.42 for Sept. 8, 2026
PE Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical PE Ratio Data
| Date | Value |
|---|---|
| September 08, 2026 | 117.42 |
| September 04, 2026 | 118.14 |
| September 03, 2026 | 119.33 |
| September 02, 2026 | 119.33 |
| September 01, 2026 | 118.38 |
| August 31, 2026 | 116.83 |
| August 28, 2026 | 118.62 |
| August 27, 2026 | 119.57 |
| August 26, 2026 | 119.57 |
| August 25, 2026 | 117.42 |
| August 24, 2026 | 117.42 |
| August 21, 2026 | 120.05 |
| August 20, 2026 | 120.41 |
| August 19, 2026 | 120.88 |
| August 18, 2026 | 116.47 |
| August 17, 2026 | 115.75 |
| August 14, 2026 | 119.93 |
| August 13, 2026 | 130.07 |
| August 12, 2026 | 131.03 |
| August 11, 2026 | 130.67 |
| August 10, 2026 | 130.91 |
| August 07, 2026 | 131.26 |
| August 06, 2026 | 131.50 |
| August 05, 2026 | 128.28 |
| August 04, 2026 | 132.10 |
| Date | Value |
|---|---|
| August 03, 2026 | 131.74 |
| July 31, 2026 | 133.77 |
| July 30, 2026 | 131.98 |
| July 29, 2026 | 131.38 |
| July 28, 2026 | 134.13 |
| July 27, 2026 | 132.82 |
| July 24, 2026 | 131.62 |
| July 23, 2026 | 130.43 |
| July 22, 2026 | 132.82 |
| July 21, 2026 | 133.59 |
| July 20, 2026 | 133.05 |
| July 17, 2026 | 132.76 |
| July 16, 2026 | 132.82 |
| July 15, 2026 | 128.04 |
| July 14, 2026 | 139.86 |
| July 13, 2026 | 132.22 |
| July 10, 2026 | 129.95 |
| July 09, 2026 | 136.69 |
| July 08, 2026 | 126.85 |
| July 07, 2026 | 123.39 |
| July 06, 2026 | 120.05 |
| July 02, 2026 | 122.79 |
| July 01, 2026 | 131.26 |
| June 30, 2026 | 119.93 |
| June 29, 2026 |
Price to Earnings Ratio (PE Ratio) Definition
The Price to Earnings Ratio (PE Ratio) is calculated by taking the stock price / EPS Diluted (TTM). This metric is considered a valuation metric that confirms whether the earnings of a company justifies the stock price. There isn't necesarily an optimum PE ratio, since different industries will have different ranges of PE Ratios. Because of this, PE Ratio is great to evaluate from a relative standpoint with other similar companies.
PE Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
PE Ratio Benchmarks
| ACADIA Pharmaceuticals, Inc. | 12.42 |
| Alnylam Pharmaceuticals, Inc. | 43.91 |
| Anika Therapeutics, Inc. | -- |
| Savara, Inc. | -- |
| Vericel Corp. | 84.53 |
PE Ratio Related Metrics
| PS Ratio | 2.913 |
| Price to Book Value | 2.848 |
| Price to Free Cash Flow | 21.20 |
| Price | 9.84 |
| Earnings Yield | 0.85% |
| Market Cap | 89.37M |
| Operating PE Ratio | 47.88 |
| Normalized PE Ratio | 71.36 |